Abstract:This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal).This article has been retracted at the request of the Editor-in-Chief and the authors, as panels from Figure 6F appear as similar to panels from Figure 2B of the article published by Ming-Quan Gao, Hui Gao, Mei Han, Kai-Li Liu, Jian-Jun Peng and Yan-Tao Han in the American Journal of Cancer Research 7 (2017) 1501–1514 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523031/ and Figures 2E and 3E of the article published by Meizhi Wang, Hui Gao, Haijun Qu, Jing Li, Kaili Liu and Zhiwu Han in Pharmacological Reports 70 (2018) 963–971 https://doi.org/10.1016/j.pharep.2018.04.006.Also, the Vehicle panel from Figure 7E appears as similar to the Vehicle panel from Figure 3D of the article published by Bo Liu and Shuo Yu in Biomedicine & Pharmacotherapy 107 (2018) 243–253 https://doi.org/10.1016/j.biopha.2018.07.177.Figure 7E appears also as similar to Figure 6(b) of the article published by Mei Han, Hui Gao, Jing Xie, Yin-ping Yuan, Quan Yuan, Ming-quan Gao, Kai-li Liu, Xue-hong Chen, Yan-tao Han and Zhi-wu Han in Acta Pharmacologica Sinica volume 40 (2019) 666–676 https://doi.org/10.1038/s41401-018-0159-7.Moreover, panels from Figure 7F appear as similar to panels from Figure 7E of the Reference [1], Figure 6D of the Reference [2], Figure 6C of the Reference [3], Figure 8C of the Reference [4], Figure 8D of the Reference [5] and Figure 6B of the Reference [6].One of the conditions of submission of a paper for publication is that authors declare explicitly that their work is original and has not appeared in a publication elsewhere. Re-use of any data should be appropriately cited. As such this article represents a severe abuse of the scientific publishing system. The scientific community takes a very strong view on this matter and apologies are offered to readers of the journal that this was not detected during the submission process.

Retracted: Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells In Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway

RETRACTED: Znhit1 Inhibits Breast Cancer by Up-Regulating PTEN to Deactivate the PI3K/Akt/mTOR Pathway

RETRACTED: Protective Autophagy Induced by Physcion Suppresses Hepatocellular Carcinoma Cell Metastasis by Inactivating the JAK2/STAT3 Axis.

Retracted: MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2)

Retracted: Apatinib plus Radiotherapy on the Expression of CEA and VEGF in Advanced Oligometastatic Non-Small-Cell Lung Cancer

[Retracted] Anticancer Activity of Caffeic Acid N‑butyl Ester Against A431 Skin Carcinoma Cell Line Occurs Via Induction of Apoptosis and Inhibition of the Mtor/pi3k/akt Signaling Pathway.

RETRACTION: MicroRNA-520a-3p suppresses epithelial-mesenchymal transition, invasion, and migration of papillary thyroid carcinoma cells via the JAK1-mediated JAK/STAT signaling pathway (Retraction of Vol 234, Pg 4054, 2019)

[Retracted] Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines

RETRACTED: Mir-221/222 Enhance the Tumorigenicity of Human Breast Cancer Stem Cells Via Modulation of PTEN/Akt Pathway

Retracted: Anticancer Action of Psilostachyin-A in 5-Fluorouracil-Resistant Human Liver Carcinoma are Mediated Through Autophagy Induction, G2/M Phase Cell Cycle Arrest and Inhibiting Extracellular-Signal-Regulated Kinase/Mitogen Activated Protein Kinase (ERK/MAPK) Signaling Pathway

RETRACTED: Physcion 8-O-β-glucopyranoside Inhibits Clear-Cell Renal Cell Carcinoma Bydownregulating Hexokinase II and Inhibiting Glycolysis.

RETRACTION: Combination of Aloin and Metformin Enhances the Antitumor Effect by Inhibiting the Growth and Invasion and Inducing Apoptosis and Autophagy in Hepatocellular Carcinoma Through PI3K/AKT/mTOR Pathway

[Retracted] Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‐152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway

Retraction Notice To: Downregulation of P53-Inducible Micrornas 192, 194, and 215 Impairs the P53/mdm2 Autoregulatory Loop in Multiple Myeloma Development.

Retracted: miR-138 Reduces the Dysfunction of T Follicular Helper Cells in Osteosarcoma via the PI3K/Akt/mTOR Pathway by Targeting PDK1

[Retracted] AdipoR1‐mediated miR‐3908 inhibits glioblastoma tumorigenicity through downregulation of STAT2 associated with the AMPK/SIRT1 pathway

[Retracted] Tunicamycin inhibits colon carcinoma growth and aggressiveness via modulation of the ERK‐JNK‐mediated AKT/mTOR signaling pathway

Retraction: Mir-1266 Suppresses The Growth And Metastasis Of Prostate Cancer Via Targeting Prmt5 (Retraction Of Vol 23, Pg 6436, 2019)

Retracted: Immunotherapy Mechanism of Esophageal Squamous Cell Carcinoma with the Effect of STK11/AMPK Signaling Pathway

Statement of Retraction: Downregulation of NEAT1 reverses the radioactive iodine resistance of papillary thyroid carcinoma cell via miR-101-3p/FN1/PI3K-AKT signaling pathway